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Background. This study examines the predictive value of eosinophilia for Strongyloides stercoralis infection, as measured by en-
zyme-linked immunosorbent assay (ELISA) testing, in an endemic community. In remote communities, eosinophilia is frequently
used as a proxy test for the presence of helminth infections. Past studies of eosinophilia and Strongyloides infection have been con-
ducted in specific groups such as immigrants and refugees, or in subpopulations of nonendemic communities, rather than in en-
demic communities.
Methods. We conducted a cross-sectional study of the relationship between eosinophilia and Strongyloides ELISA serology, as
part of a study into the relationship between S stercoralis infection and type 2 diabetes mellitus (T2DM) in an Indigenous community
in northern Australia.
Results. Two hundred thirty-nine adults had their eosinophil count and S stercoralis ELISA serology measured in 2012 and 2013,
along with other biometric and metabolic data. Eosinophilia was found to have a relatively poor sensitivity (60.9%), specificity
(71.1%), positive predictive value (54.6%), and negative predictive value (76.1%) for S stercoralis ELISA positivity in this group. How-
ever, there was a more constant relationship between eosinophilia and S Stercoralis ELISA positivity in patients with T2DM (negative
predictive value 87.5%).
Conclusions. This study suggests that the presence or absence of eosinophilia is not an adequate proxy test for S stercoralis
infection in a community where the infection is prevalent, and that the association between eosinophilia and S stercoralis ELISA
positivity is more constant in patients with T2DM.
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Infection with the soil-transmitted helminth Strongyloides ster-
coralis is endemic in many of the Indigenous communities of
northern Australia, with prevalence of up to 41% recorded in
some locations [1].
Direct microbiological tests to diagnose the infection are
often impractical in these settings because multiple fresh fecal
samples are required, and sensitivity is low even in ideal circum-
stances. The use of enzyme-linked immunosorbent assay
(ELISA) serology in the diagnosis of Strongyloides infection
and in conducting prevalence surveys has, in the past, been
contentious. Uncertainties exist over the meaning of positive
ELISA results, what level of ELISA test should be considered
positive, and whether antibodies persevere after the resolution
of infection. In addition, cross-reactivity with other helminth
infections was considered to be a problem, particularly with ear-
lier versions of the test. However, recent studies suggest that the
use of an ELISA test to detect antibodies to the worm is both
sensitive and specific enough to diagnose the infection and de-
termine the success of treatment, and its use is now widespread
in clinical practice [2–4]. However, this test is currently not
available in a point-of-care format, and therefore it entails
transport of specimens to central laboratories with significant
delays in diagnosis and treatment for patients in remote
locations.
Eosinophilia is a common, but not uniform, finding in S ster-
coralis infection and is thought to be more marked in earlier in-
fections, becoming less pronounced and more variable in
chronic cases [5]. Several studies have addressed the relationship
between eosinophilia and Strongyloides infection in the context
of patient screening, but these have been conducted in migrant
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and traveler populations, or in subpopulations of nonendemic
societies [6–12], and have often not addressed the prevalence
of Strongyloides in patients without eosinophilia.
Infections that are endemic to northern Australia and that are
known to produce eosinophilia include Trichuris trichuria,
hookworm species, Hymenolepis nana, Toxocara canis, Giardia
duodenalis, and S stercoralis [13], as well as ectoparasites such as
Sarcoptes scabiei, resulting in eosinophilia being a common
finding in this region.
As part of a study conducted into the relationship between
type 2 diabetes mellitus (T2DM) and S stercoralis infection,
we examined the prevalence of eosinophilia in relation to
Strongyloides infection, as measured by ELISA serology, in an
Aboriginal community. Data from this study demonstrated a
negative relationship between S Stercoralis infection and
T2DM [1], and these data have suggested that T2DM is a pre-
dictor of treatment failure in this setting [14]. Eosinophilia is
thought to be central to the process by which helminth infec-
tions can affect the metabolic status of infected subjects through
a process of immunomodulation [15].
This study provides, for the first time, data on the predictive
value of eosinophilia in the diagnosis of S stercoralis infection in
an endemic community and analyses this in the context of T2DM.
MATERIALS AND METHODS
The study was conducted in 3 related Indigenous communities,
located within a 100 km radius in the Tanami desert region of
Western Australia. Opportunistic testing for, and treatment of,
S stercoralis was commenced in these communities in 2012 ac-
cording to the best practice guidelines of the Australian Strong-
yloides working group [16].
Strongyloides stercoralis ELISA testing was ordered, often in
conjunction with other routine laboratory investigations. Testing
was performed by Pathwest Laboratory in Perth Western Austra-
lia, using the commercial Strongyloides IgG ELISA (DRG labo-
ratory). The reference values, in units of absorbance, for this test
were as follows: less than 0.2 −Negative; 0.2 to 0.4 −Equivocal;
>0.4 −Positive. However, as was noted by the laboratory, these
ranges were developed in a metropolitan population where the
prevalence of S stercoralis was very low (manufacturers informa-
tion). To reduce the possibility of false-negative results, a modi-
fied range was used. All values greater than or equal to 0.30 were
considered positive and treated. All values <0.30 were considered
equivocal and were retested after a period of 6 months, to ascer-
tain the rate of seroconversion (and presumably therefore new in-
fections) in this group. Only 3 seroconversions were found in this
time, and the analysis for this study was performed using the re-
sults of the initial testing only.
Data were extracted including the age, sex, date of testing, S
stercoralis ELISA titer hemoglobin, total eosinophil count, per-
centage eosinophilia, height, weight, calculated body mass index
(BMI), diabetic status and HbA1C triglyceride level, high-
density lipoprotein, and total cholesterol. The study population
for this study was identical to that in our 2 previous studies in
this community [1, 14].
Eosinophilia was defined as a total eosinophil count of
0.50 × 109/L or greater. Diabetes was defined in this group as
an HbA1C reading of 6.5% or greater, or a random blood glu-
cose of more than 11.1 mmol/L, or a fasting blood glucose of
more than 7.0 mmol/L, either at the time of testing, or in the
past in patients already receiving treatment for diabetes.
Ethical Approval
The protocol for this study was approved in principle by the
Kimberley Aboriginal Health Planning Forum. All participant
were 21 years of age or older. Because no investigations or treat-
ments apart from those required for best clinical practice were
being performed, and literacy levels are very low in the study
population, verbal consent was considered appropriate. Verbal
consent was obtained from all participants and recorded elec-
tronically. Formal ethical approval was granted by the Western
Australian Aboriginal Health Ethics Committee (HREC:515).
Statistical Analysis
Descriptive statistics, including means, medians, percentages,
and their respective 95% confidence intervals (CIs), were used
to analyze the demographic and clinical characteristics of par-
ticipants. The accuracy of eosinophilia (≥0.50) as a measure of S
stercoralis status (E-titer ≥0.30) was evaluated using sensitivity
and specificity measures. To account for the high prevalence of
S stercoralis, the positive predictive value (PPV) and negative
predictive value (NPV) for the ≥0.50 eosinophilia cutoff were
also calculated. These diagnostic test evaluations were also un-
dertaken separately for participants with and without diabetes.
Four logistic regression analyses were undertaken to examine
the association between diabetes status and the sensitivity, spe-
cificity, PPV, and NPV of eosinophilia as measure of S stercor-
alis. As a first step, dichotomous variables were created to flag
participants that were true-positive cases (eosinophilia ≥0.50
and E-titer ≥0.30) or true-negative cases (eosinophilia <0.50
and E-titer <0.30).
The sensitivity regression was the odds of diabetic participants
with S stercoralis having a positive eosinophilia diagnosis (true
positive) compared with the odds of the same true-positive diag-
nosis among nondiabetic participants. The specificity regression
was the odds of a true negative diagnosis by these diabetes groups.
Analysis of PPV was the odds of a true-positive diagnosis
among diabetic patients with a positive eosinophilia compared
with nondiabetic patients. The NPV regression was the odds of
true-negative diagnosis among those with a negative eosinophil-
ia result, again by diabetes status.
All regression analyses were also adjusted for sex, age, BMI,
and previous anthelminthic treatment with albendazole. Cases
with missing values on any of these variables were dropped
from the adjusted modeling. A 5% significance level was used
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for all statistical tests, and all analyses were undertaken using
Stata, version 13 (StataCorp, 2013; Stata Statistical Software: Re-
lease 13; StataCorp LP, College Station, TX).
RESULTS
Two hundred fifty-nine patients were screened, with 92 (35.5%;
95% CI, 29.9%–41.6%) cases of Strongyloides infection, as indi-
cated by ELISA serology of ≥0.30, diagnosed. However, eosin-
ophil counts were available for only 239 patients, with the
missing values being due to specimen degradation during trans-
port. Of the 20 degraded specimens, 5 were positive for S ster-
coralis by ELISA testing and 7 had T2DM. Table 1 details the
clinical characteristics of the 239 patients with both ELISA test-
ing results and eosinophil counts.
Table 2 shows that 97 patients had eosinophilia, giving an
overall prevalence of 40.6% (95% CI, 34.5%–47.0%). In the in-
fected patients, the prevalence was 60.9% (50.1%–70.7%). The
prevalence of eosinophilia was similar in diabetic compared
with nondiabetic subjects (41.9% [95% CI, 33.5%–50.9%] and
39.1% [95% CI, 30.5%–48.5%], respectively; odds ratio
[OR] = 1.12, 95% CI, .67%–1.88, P = .659), whereas the preva-
lence of eosinophilia was higher in infected diabetics compared
with infected nondiabetics, although this difference did not
reach statistical significance (71.0% [95% CI, 51.8%–84.8%]
and 55.4% [95% CI, 41.9%–68.1%], respectively; OR = 1.97,
95% CI, .77%–5.03, P = .156).
One quarter (25.0%) of the diabetic patients had a positive S
stercoralis ELISA test compared with almost half of the nondi-
abetic patients (48.7%). Eosinophilia as a test for S stercoralis
had a sensitivity of 60.9% and a specificity of 71.1% (Table 3).
Eosinophilia had an overall PPV of 54.6% and a NPV of 76.1%.
The NPV of eosinophilia was higher in diabetic patients (87.5%,
95% CI, 77.6–94.1) compared with nondiabetic patients (64.3%,
95% CI, 51.9–75.4).
Because the ELISA cutoff level of 0.30 units was used in this
study for purely clinical reasons, the analysis was repeated using
the conventional cutoff of 0.40 units (Supplementary Tables 1–
3) and again using a higher cutoff of 0.50 for the purposes of com-
parison. The NPV of eosinophilia remained high for both cutoff
levels (81.0% for ≥0.40 and 86.6% for ≥0.50), and the differences
between diabetic and nondiabetic patients remained comparable.
Logistic regression (Table 4) showed that among the 97 pa-
tients with eosinophilia, the odds of having a positive S stercor-
alis ELISA test (PPV) were 67% lower among diabetic patients
compared with those without diabetes (OR = 0.33, 95% CI,
.14–.77, P = .010). This difference remained after adjusting for
age, sex, weight, BMI, and past treatment with anthelminthic
drugs (n = 95, OR = 0.30, 95% CI, .11–.81, P = .018). In compar-
ison, diabetics without eosinophilia were almost 4 times more
likely to also have a negative S stercoralis ELISA test (NPV),
compared with nondiabetic patients without eosinophilia
(n = 142, OR = 3.89, 95% CI, 1.66–9.12, P = .002). This differ-
ence remained after adjustment, although 14 patients were ex-
cluded due to missing values on potential confounding
variables (n = 128, OR = 4.51, 95% CI, 1.73–11.76, P = .002).
DISCUSSION
This study suggests that eosinophilia alone cannot be used to
infer the presence of Strongyloides infection in patients from In-
digenous communities where the condition is endemic. This is
Table 1. Clinical Characteristics of Study Participants (n = 239)
Variable N Mean, Median or % 95% CI, IQR
Age (years) 239 43.6 (41.8–45.5)
Male 99 41.4% (35.8–48.4)
Weight (kg) 235 81.0 (78.2–83.8)
BMI (kg/m2) 226 29.5 (28.5–30.5)
Hb (g/L) 237 133.6 (131.4–135.7)
HbA1c % 204 6.8a (5.9–8.9)
SBP (mmHg) 239 126.8 (124.4–129.3)
DBP (mmHg) 239 79.5 (78.0–80.9)
Cholesterol (mmol/L) 212 4.6 (4.4–4.7)
HDL (mmol/L) 211 0.90 (.87–.93)
Triglycerides (mmol/L) 211 2.1a (1.4–3.0)
Diabetes 124 51.9% (45.3–58.1)
Eosinophil count 239 0.43a (.26–.71)
Eosinophil % 238 5.55a (3.40–8.50)
E (ELISA) titer 239 0.15a (.08–.49)
%E-titer ≥0.3 87 36.4% (30.5–42.8)
Past anthelminthic therapy 72 30.1% (24.9–36.7)
Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure;
ELISA, enzyme-linked immunosorbent assay; Hb, hemoglobin; HDL, high-density
lipoprotein; IQR, interquartile range; SBP, systolic blood pressure.
a Median and IQR.
Table 2. Prevalence of Eosinophilia (≥0.5) and Strongyloides stercoralis
(E-Titer ≥0.3) by Diabetes Status
Diabetes
Status
Eosinophils
Measure
S stercoralis Serology Status (ELISA
Titer)
Positive
(% E-Titer
≥0.3)
Negative
(% E-Titer
<0.3) Total
n % n % N %
Nondiabetic 56 48.7 59 51.3 115 100.0
Eosinophilia (≥0.5) 31 68.9 14 31.1 45 100.0
Noneosinophilia
(<0.5)
25 35.7 45 64.3 70 100.0
Diabetic 31 25.0 93 75.0 124 100.0
Eosinophilia (≥0.5) 22 42.3 30 57.7 52 100.0
Noneosinophilia
(<0.5)
9 12.5 63 87.5 72 100.0
Total 87 36.4 152 63.6 239 100.0
Eosinophilia (≥0.5) 53 54.6 44 45.4 97 100.0
Noneosinophilia
(<0.5)
34 23.9 108 76.1 142 100.0
Bold value indicates total numbers in each category.
Abbreviation: ELISA, enzyme-linked immunosorbent assay.
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perhaps not a surprising finding given the large number of
other parasitic infections that are present in these communities
and capable of causing eosinophilia.
However, the relatively low NPV of eosinophilia was more
notable, suggesting that the absence of eosinophilia does not re-
liably rule out the diagnosis of Strongyloides infection in this
setting. In fact, in this study, almost one quarter of patients
without eosinophilia had positive Strongyloides ELISA serology.
This is of relevance to clinicians because, in a remote setting, the
absence of eosinophilia is often used as a proxy test to imply the
absence of parasitic infection. This study suggests that such a
practice would not be safe as a means to exclude Strongyloides
infection, particularly in situations in which the patient faces
immunosuppression or chemotherapy. Immunosuppression
and or steroid therapy in the presence of undiagnosed Strong-
yloides infection can lead to hyperinfection syndrome, often
with fatal consequences [17].
The findings are similar to those of Naidu et al [7] in their
survey of refugee populations in Canada, where they are also
at pains to point out that the absence of eosinophilia should
not be used to infer the absence of Strongyloides infection. How-
ever, they are at odds with a survey of farm workers carried out
in southern Spain where the results suggested that eosinophilia
had a specificity of 93.1% and sensitivity of 93.5%, and the au-
thors recommended public health screening for strongyloidiasis
using eosinophilia [12]. It is clear that the situation in this com-
munity is quite different, with a low level of transmission overall
and the absence of other significant parasitic infections. This
disparity can also be explained in part by differences in the
method of diagnosis used. The Spanish study used microbiolog-
ical examination of stool specimens for diagnosis, a method that
is known to have a low sensitivity, and to be influenced by the
worm burden and subsequent numbers of larvae shed in the
feces [2]. Eosinophilia is known to be more common in early
Table 3. Predictive Value of Eosinophilia (≥0.5) for Strongyloides stercoralis Status Determined by Serology (E-Titer ≥0.3)
Parameters
Nondiabetic (n = 115) Diabetic (n = 124) Total (n = 239)
n (%) n (%) n (%)
True negatives 45 (39.1) 63 (50.8) 108 (45.2)
False positives 14 (12.2) 30 (24.2) 44 (18.4)
True positives 31 (27.0) 22 (17.7) 53 (22.2)
False negatives 25 (21.7) 9 (7.3) 34 (14.2)
(%) (95% CI) (%) (95% CI) (%) (95% CI)
Sensitivity (55.4) (41.5–68.7) (71.0) (52–85.8) (60.9) (49.9–71.2)
Specificity (76.3) (63.4–86.4) (67.7) (57.3–77.1) (71.1) (63.2–78.1)
Positive predictive value (68.9) (53.4–81.8) (42.3) (28.7–56.8) (54.6) (44.2–64.8)
Negative predictive value (64.3) (51.9–75.4) (87.5) (77.6–94.1) (76.1) (68.2–82.8)
Abbreviation: CI, confidence interval.
Table 4. Logistic Regression Analyses of Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value by Diabetes Status
Analysis Diabetes Status
Unadjusted OR Adjusted ORa
n OR (95% CI) n OR (95% CI)
Analysis of sensitivity 87 82
Nondiabetic 56 1.00 52 1.00
Diabetic 31 1.97 (.77–5.03) 30 2.07 (.73–5.84)
Analysis of specificity 152 141
Nondiabetic 59 1.00 55 1.00
Diabetic 93 0.65 (.31–1.37) 86 0.74 (.33–1.66)
Analysis of positive predictive value 97 95
Nondiabetic 45 1.00 43 1.00
Diabetic 52 0.33 (.14–.77)* 52 0.30 (.11–.81)*
Analysis of negative predictive value 142 128
Nondiabetic 70 1.00 64 1.00
Diabetic 72 3.89 (1.66–9.12)* 64 4.51 (1.73–11.76)*
Bold value indicates total numbers in each category.
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Adjusted for sex, age, BMI, and past antibiotic treatment.
*P < .05.
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or acute Strongyloides infections, when worm burden and larval
counts are highest, and to decline and become more variable in
chronic infection, presumably through the mechanism of para-
site-induced immunomodulation in the host [5, 18]. Use of
fecal testing for diagnosis would therefore tend to select earlier
infections, with higher worm counts and therefore higher rates
of eosinophilia, whereas ELISA testing would detect more
chronic infections where immunomodulation had resulted in
more variable eosinophilia.
This study found that the prevalence of eosinophilia in diabetic
subjects was no different to that in nondiabetic. This is at odds
with the findings of a much larger cross-sectional study performed
in China that demonstrated a negative relationship between eosin-
ophilia and insulin resistance and T2DM [19]. However, the Chi-
nese study was conducted in a population where both helminth
infection and eosinophilia are less prevalent and where other,
noninfectious causes of eosinophilia are likely to be more
common.
Data from this community published elsewhere demonstrate
a negative relationship between Strongyloides infection and
T2DM [1]. It is postulated that this effect is again due to para-
site-induced immunomodulation affecting the hosts’ metabolic
system in chronic infections and resulting in increased insulin
sensitivity. Laboratory evidence suggests that eosinophilic infil-
tration of adipose tissue due to helminth infection promotes the
presence of alternatively activated macrophages, which in turn
act to increase insulin sensitivity [15].
However, this study showed a higher prevalence of eosino-
philia in ELISA-positive diabetics and demonstrates that the ab-
sence of eosinophilia in diabetic subjects is more closely linked
with the absence of Strongyloides antibodies. This might be ex-
plained if the diabetic group contains a greater proportion of
acute or recent infections, resulting in a more marked eosino-
philia, as opposed to chronic and immune-modulated infec-
tions, where eosinophilia is less pronounced and where the
past eosinophilic infiltration of adipose tissue has contributed
to a lower prevalence of T2DM.
It is equally plausible that T2DM itself is responsible for the
higher rate of eosinophilia. A recently published paper looked at
the relationship between the human adipokine resistin and mul-
tiple helminth infections. It found that higher resistin levels
were associated with a more pronounced inflammatory re-
sponse, a higher worm burden, and reduced worm clearance
[20]. Type 2 diabetes mellitus along with obesity and metabolic
syndrome has been variably linked with elevated levels of resis-
tin [21]. In addition, data from this study published elsewhere
found that T2DM was associated with treatment failure in
Strongyloides infection, suggesting that the immune response
may be altered in diabetics [14].
Perceived weaknesses of this study may be that it relies on ELISA
serology alone for diagnosis rather than microscopy, which is the
most specific test; however, we believe this is outweighed by the
superior sensitivity of the serological test. It is clear that the num-
bers involved in this study are small, and further larger studies may
be of benefit. In addition, no distinction was made between mild,
moderate, and severe eosinophilia, with the single cutoff point of
0.5 × 109/L being used. It may be that using a lower threshold for
eosinophilia might improve the NPV of the test.
CONCLUSIONS
This study supports the use of ELISA testing for Strongyloides in-
fection as a screening test for patients in endemic Aboriginal com-
munities regardless of their eosinophilia status, and it suggests the
practice of presuming the absence of infection in patients without
eosinophilia is not a safe one. It may be that the absence of eosin-
ophilia might be of some use in the decision to screen or treat for
strongyloidiasis in the diabetic population in this community.
Further studies would be needed to assess whether this is the
case in other settings where the disease is endemic and to further
examine the link between eosinophilia and T2DM.
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Supplementary material is available online at Open Forum Infectious Dis-
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